The article details the significant progress in targeting the KRAS protein, a notorious cancer driver long considered ‘undruggable.’ It explains how recent scientific breakthroughs, particularly the development of covalent inhibitors that bind to a specific mutant form (G12C), have changed the landscape. These drugs, like sotorasib and adagrasib, represent a new class of targeted therapy for lung and colorectal cancers. The piece also explores ongoing challenges, such as drug resistance and targeting other KRAS mutations, and highlights next-generation strategies including combination therapies and pan-KRAS inhibitors. The progress marks a pivotal shift in oncology drug development. Read the full article for a detailed analysis.